IA Insight Report
IA Insight REPORT

DPMS - Pharma

Investment Approach Details

₹2.29

(AUM CR)
   

Klay Securities Private Limited

S&P BSE 500 TRI

Equity

Equity

24/11/2021

2.5 Years

5000000

Management Fees: 2%

Hurdle Rate: 8% Profit Sharing: 20%

1st Year: 3% 2nd Year: 2% 3rd Year: 1%

   

Creating significant value over long term by investing in a concentrated portfolio of Indian Pharma and Healthcare Sector by investing in securities which are significantly below fair value and with strong long-term prospects.

Fund Manager Details

IAN DSOUZA

No Image

NA

ian@klaycapital.in

NA

NA

Period-Wise Performance

IA vs. Benchmark Performance

Turnover Details As On 31/03/2024

0.19

1.01